Induction Chemotherapy in Patients With Anal Canal Cancer: A Pilot Study

2020 ◽  
Vol 19 (3) ◽  
pp. e137-e139
Author(s):  
Francesca De Felice ◽  
Daniela Musio ◽  
Vincenzo Tombolini
Keyword(s):  
Pilot Study ◽  
Anal Canal ◽  
Induction Chemotherapy ◽  
Anal Canal Cancer

The INCH Trial – Induction Chemotherapy in Patients With Bulky Anal Canal Cancer: Evaluation of the Pilot Phase

2021 ◽  
Vol 41 (6) ◽  
pp. 3187-3191
Author(s):  
FRANCESCA DE FELICE ◽  
ALESSIA FALLARINO ◽  
FRANCO IAFRATE ◽  
VERONICA MAIURI ◽  
GIOVANNI GALLONI ◽  
...  
Keyword(s):  
Anal Canal ◽  
Induction Chemotherapy ◽  
Anal Canal Cancer ◽  
Pilot Phase

PO-1266 Induction chemotherapy in bulky HPV-negative anal canal cancer

2021 ◽  
Vol 161 ◽  
pp. S1044-S1045
Author(s):  
F. De Felice ◽  
A. Fallarino ◽  
F. Iafrate ◽  
V. Maiuri ◽  
G. Galloni ◽  
...  
Keyword(s):  
Anal Canal ◽  
Induction Chemotherapy ◽  
Anal Canal Cancer

Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience

2007 ◽  
Vol 25 (29) ◽  
pp. 4581-4586 ◽  
Author(s):  
Joseph K. Salama ◽  
Loren K. Mell ◽  
David A. Schomas ◽  
Robert C. Miller ◽  
Kiran Devisetty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Anal Canal ◽  
Cancer Patients ◽  
Intensity Modulated Radiation Therapy ◽  
Complete Response ◽  
Concurrent Chemotherapy ◽  
Hiv Positive ◽  
Anal Canal Cancer ◽  
Intensity Modulated ◽  
Dermatologic Toxicity

PurposeTo report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT).Patients and MethodsFrom October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography–based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria.ResultsMedian follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively.ConclusionPreliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

scholarly journals Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: A pilot study

Head & Neck ◽  
2014 ◽  
Vol 37 (4) ◽  
pp. 567-572 ◽  
Author(s):  
Bharat B. Mittal ◽  
Barbara Roa Pauloski ◽  
Alfred W. Rademaker ◽  
Muveddet Discekici-Harris ◽  
Irene B. Helenowski ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Pilot Study ◽  
Head And Neck ◽  
Induction Chemotherapy ◽  
Neck Cancer ◽  
Swallow Physiology ◽  
Saliva Production

Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study

2016 ◽  
Vol 130 (9) ◽  
pp. 833-842 ◽  
Author(s):  
V Noronha ◽  
C Goswami ◽  
S Patil ◽  
A Joshi ◽  
V M Patil ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Pilot Study ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Induction Chemotherapy ◽  
Squamous Cell ◽  
Response Rate ◽  
Locally Advanced ◽  
Comparable Efficacy ◽  
Induction Regimen

AbstractBackground:Docetaxel, cisplatin plus 5-fluorouracil is an efficacious induction regimen but is more toxic than cisplatin plus 5-fluorouracil. This study aimed to determine whether docetaxel and cisplatin without 5-fluorouracil maintains efficacy while decreasing toxicity.Methods:A multicenter non-comparative pilot study of locally advanced squamous cell carcinoma of the head and neck was performed. Patients received primary therapy comprising three cycles of 75 mg/m2 docetaxel and 75 mg/m2 cisplatin followed by concurrent chemoradiotherapy. The primary endpoint was the response rate to the docetaxel and cisplatin induction regimen.Results:A total of 26 patients were enrolled: of these, 23 (88.5 per cent) received all three docetaxel and cisplatin cycles. Common grade 3–4 adverse events were febrile neutropenia (19.2 per cent of patients), diarrhoea (19.2 per cent) and non-neutropenic infection (15.4 per cent). The overall response rate to docetaxel and cisplatin induction chemotherapy was 65.4 per cent. A total of 23 patients (88.5 per cent) subsequently received chemoradiotherapy with a median radiotherapy dose of 70 Gy. The response rate to chemoradiotherapy was 73 per cent. At a median follow up of 44 months, the 3-year progression-free survival and overall survival rates were 62 per cent and 69 per cent, respectively.Conclusion:Docetaxel and cisplatin induction chemotherapy is a feasible induction regimen with comparable efficacy to docetaxel, cisplatin and 5-fluorouracil induction chemotherapy.

scholarly journals Clinical case of a metastatic squamous anal canal cancer with benefit of Cetuximab - What do we know about anti EGFR?

2018 ◽  
Vol 3 (1) ◽  
Author(s):  
Losada B ◽  
Pulido G ◽  
Cervera R ◽  
Ibeas P ◽  
Perezagua C
Keyword(s):  
Anal Canal ◽  
Clinical Case ◽  
Anal Canal Cancer

scholarly journals Carcinoma of the anal canal

2011 ◽  
Vol 3 (1) ◽  
pp. 27
Author(s):  
David T. Marshall ◽  
Charles R. Thomas Jr
Keyword(s):  
Anal Canal ◽  
Locally Advanced ◽  
The United States ◽  
Sphincter Preservation ◽  
Tumor Control ◽  
Anal Canal Cancer ◽  
Permanent Colostomy ◽  
Anti Cancer ◽  
Treatment Paradigm ◽  
Technological Developments

There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that

scholarly journals Clinicopathological studies of anal canal cancer.

1989 ◽  
Vol 22 (10) ◽  
pp. 2414-2420 ◽  
Author(s):  
Ken HAYASHI ◽  
Teruyuki HIROTA ◽  
Masayuki ITABASHI ◽  
Keiichi HOJO ◽  
Yoshihiro MORIYA ◽  
...  
Keyword(s):  
Anal Canal ◽  
Anal Canal Cancer

Feasibility of Induction Chemotherapy Using Bronchial Arterial Infusion for Locally Advanced Non-Small Cell Lung Cancer: A Pilot Study

Surgery Today ◽  
2002 ◽  
Vol 32 (9) ◽  
pp. 772-778 ◽  
Author(s):  
Toshihiro Osaki ◽  
Tsunehiro Oyama ◽  
Mitsuhiro Takenoyama ◽  
Satoshi Taga ◽  
Tomoko So ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Induction Chemotherapy ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Arterial Infusion ◽  
Bronchial Arterial Infusion
Sign in / Sign up

Export Citation Format

Share Document